Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

Scand J Rheumatol. 2010;39(1):97-8. doi: 10.3109/03009740903177745.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / blood*
  • Antirheumatic Agents / administration & dosage*
  • Antirheumatic Agents / blood*
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Infliximab
  • Infusions, Intravenous
  • Long-Term Care
  • Male
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Predictive Value of Tests
  • Risk Assessment
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / diagnosis
  • Spondylitis, Ankylosing / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab